nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluticasone Propionate—PLA2G4A—Epirubicin—sarcoma	0.488	0.611	CbGbCtD
Fluticasone Propionate—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.0556	0.0696	CbGbCtD
Fluticasone Propionate—CYP3A7—Vincristine—sarcoma	0.0556	0.0696	CbGbCtD
Fluticasone Propionate—CYP3A4—Thiotepa—sarcoma	0.055	0.0688	CbGbCtD
Fluticasone Propionate—CYP3A5—Vincristine—sarcoma	0.0417	0.0522	CbGbCtD
Fluticasone Propionate—CYP3A5—Etoposide—sarcoma	0.0382	0.0478	CbGbCtD
Fluticasone Propionate—CYP3A4—Mitoxantrone—sarcoma	0.0236	0.0296	CbGbCtD
Fluticasone Propionate—CYP3A4—Vincristine—sarcoma	0.0163	0.0204	CbGbCtD
Fluticasone Propionate—CYP3A4—Etoposide—sarcoma	0.0149	0.0187	CbGbCtD
Fluticasone Propionate—CYP3A4—Doxorubicin—sarcoma	0.0102	0.0127	CbGbCtD
Fluticasone Propionate—PGR—mammary gland—sarcoma	0.00192	0.041	CbGeAlD
Fluticasone Propionate—PLA2G4A—myometrium—sarcoma	0.0018	0.0385	CbGeAlD
Fluticasone Propionate—PLA2G4A—seminal vesicle—sarcoma	0.00163	0.0348	CbGeAlD
Fluticasone Propionate—PLA2G4A—hematopoietic system—sarcoma	0.00155	0.0331	CbGeAlD
Fluticasone Propionate—SERPINA6—hematopoietic system—sarcoma	0.00154	0.0329	CbGeAlD
Fluticasone Propionate—PLA2G4A—connective tissue—sarcoma	0.00149	0.0318	CbGeAlD
Fluticasone Propionate—NR3C2—myometrium—sarcoma	0.00147	0.0313	CbGeAlD
Fluticasone Propionate—PLA2G4A—smooth muscle tissue—sarcoma	0.00136	0.0291	CbGeAlD
Fluticasone Propionate—PGR—myometrium—sarcoma	0.00136	0.0291	CbGeAlD
Fluticasone Propionate—NR3C2—seminal vesicle—sarcoma	0.00132	0.0283	CbGeAlD
Fluticasone Propionate—NR3C2—hematopoietic system—sarcoma	0.00126	0.0269	CbGeAlD
Fluticasone Propionate—NR3C2—connective tissue—sarcoma	0.00121	0.0259	CbGeAlD
Fluticasone Propionate—PGR—hematopoietic system—sarcoma	0.00117	0.025	CbGeAlD
Fluticasone Propionate—PGR—connective tissue—sarcoma	0.00113	0.0241	CbGeAlD
Fluticasone Propionate—NR3C2—smooth muscle tissue—sarcoma	0.00111	0.0237	CbGeAlD
Fluticasone Propionate—PGR—smooth muscle tissue—sarcoma	0.00103	0.022	CbGeAlD
Fluticasone Propionate—PLA2G4A—tendon—sarcoma	0.00102	0.0219	CbGeAlD
Fluticasone Propionate—CYP3A7—liver—sarcoma	0.001	0.0214	CbGeAlD
Fluticasone Propionate—PLA2G4A—bone marrow—sarcoma	0.000992	0.0212	CbGeAlD
Fluticasone Propionate—SERPINA6—bone marrow—sarcoma	0.000988	0.0211	CbGeAlD
Fluticasone Propionate—NR3C2—cardiac atrium—sarcoma	0.000955	0.0204	CbGeAlD
Fluticasone Propionate—NR3C2—uterus—sarcoma	0.00095	0.0203	CbGeAlD
Fluticasone Propionate—PGR—uterus—sarcoma	0.000883	0.0189	CbGeAlD
Fluticasone Propionate—CYP3A7-CYP3A51P—liver—sarcoma	0.000851	0.0182	CbGeAlD
Fluticasone Propionate—PLA2G4A—testis—sarcoma	0.000848	0.0181	CbGeAlD
Fluticasone Propionate—NR3C2—tendon—sarcoma	0.000833	0.0178	CbGeAlD
Fluticasone Propionate—PGR—lymphoid tissue—sarcoma	0.000823	0.0176	CbGeAlD
Fluticasone Propionate—SERPINA6—liver—sarcoma	0.000798	0.0171	CbGeAlD
Fluticasone Propionate—NR3C1—myometrium—sarcoma	0.000786	0.0168	CbGeAlD
Fluticasone Propionate—NR3C1—embryo—sarcoma	0.000756	0.0162	CbGeAlD
Fluticasone Propionate—PGR—Ovarian Infertility Genes—GJA4—sarcoma	0.000728	0.0719	CbGpPWpGaD
Fluticasone Propionate—NR3C1—seminal vesicle—sarcoma	0.00071	0.0152	CbGeAlD
Fluticasone Propionate—NR3C2—testis—sarcoma	0.00069	0.0147	CbGeAlD
Fluticasone Propionate—CYP3A5—hematopoietic system—sarcoma	0.00068	0.0145	CbGeAlD
Fluticasone Propionate—NR3C1—hematopoietic system—sarcoma	0.000675	0.0144	CbGeAlD
Fluticasone Propionate—NR3C2—liver—sarcoma	0.000652	0.0139	CbGeAlD
Fluticasone Propionate—NR3C1—connective tissue—sarcoma	0.00065	0.0139	CbGeAlD
Fluticasone Propionate—PGR—testis—sarcoma	0.000641	0.0137	CbGeAlD
Fluticasone Propionate—PLA2G4A—lymph node—sarcoma	0.000615	0.0131	CbGeAlD
Fluticasone Propionate—NR3C1—smooth muscle tissue—sarcoma	0.000594	0.0127	CbGeAlD
Fluticasone Propionate—NR3C1—skin of body—sarcoma	0.000587	0.0125	CbGeAlD
Fluticasone Propionate—NR3C1—cardiac atrium—sarcoma	0.000512	0.011	CbGeAlD
Fluticasone Propionate—CYP3A4—hematopoietic system—sarcoma	0.00051	0.0109	CbGeAlD
Fluticasone Propionate—NR3C1—uterus—sarcoma	0.00051	0.0109	CbGeAlD
Fluticasone Propionate—NR3C2—lymph node—sarcoma	0.0005	0.0107	CbGeAlD
Fluticasone Propionate—NR3C1—lymphoid tissue—sarcoma	0.000475	0.0102	CbGeAlD
Fluticasone Propionate—PGR—lymph node—sarcoma	0.000465	0.00993	CbGeAlD
Fluticasone Propionate—NR3C1—tendon—sarcoma	0.000447	0.00955	CbGeAlD
Fluticasone Propionate—Anxiety—Thiotepa—sarcoma	0.000445	0.00309	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000444	0.00308	CcSEcCtD
Fluticasone Propionate—Dermatitis contact—Doxorubicin—sarcoma	0.000442	0.00307	CcSEcCtD
Fluticasone Propionate—Discomfort—Dactinomycin—sarcoma	0.000438	0.00304	CcSEcCtD
Fluticasone Propionate—Influenza like illness—Doxorubicin—sarcoma	0.000434	0.00302	CcSEcCtD
Fluticasone Propionate—NR3C1—bone marrow—sarcoma	0.000433	0.00925	CbGeAlD
Fluticasone Propionate—Hypoaesthesia—Etoposide—sarcoma	0.000431	0.00299	CcSEcCtD
Fluticasone Propionate—Agitation—Vincristine—sarcoma	0.000428	0.00297	CcSEcCtD
Fluticasone Propionate—Vision blurred—Mitoxantrone—sarcoma	0.000427	0.00297	CcSEcCtD
Fluticasone Propionate—Candida infection—Doxorubicin—sarcoma	0.000427	0.00297	CcSEcCtD
Fluticasone Propionate—Infection—Thiotepa—sarcoma	0.000425	0.00296	CcSEcCtD
Fluticasone Propionate—Oedema—Dactinomycin—sarcoma	0.000425	0.00295	CcSEcCtD
Fluticasone Propionate—Infection—Dactinomycin—sarcoma	0.000422	0.00293	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Mitoxantrone—sarcoma	0.00042	0.00292	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Thiotepa—sarcoma	0.00042	0.00292	CcSEcCtD
Fluticasone Propionate—Tachycardia—Thiotepa—sarcoma	0.000418	0.0029	CcSEcCtD
Fluticasone Propionate—Skin disorder—Thiotepa—sarcoma	0.000416	0.00289	CcSEcCtD
Fluticasone Propionate—Malaise—Mitoxantrone—sarcoma	0.000409	0.00284	CcSEcCtD
Fluticasone Propionate—Eye disorder—Etoposide—sarcoma	0.000405	0.00281	CcSEcCtD
Fluticasone Propionate—Diabetes mellitus—Epirubicin—sarcoma	0.000403	0.0028	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Etoposide—sarcoma	0.000402	0.00279	CcSEcCtD
Fluticasone Propionate—Hypertension—Vincristine—sarcoma	0.000402	0.00279	CcSEcCtD
Fluticasone Propionate—Cough—Mitoxantrone—sarcoma	0.000395	0.00275	CcSEcCtD
Fluticasone Propionate—Hypertension—Mitoxantrone—sarcoma	0.000391	0.00272	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Etoposide—sarcoma	0.000391	0.00272	CcSEcCtD
Fluticasone Propionate—Eczema—Epirubicin—sarcoma	0.00039	0.00271	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Etoposide—sarcoma	0.00039	0.00271	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00039	0.00271	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000387	0.00269	CcSEcCtD
Fluticasone Propionate—Chest pain—Mitoxantrone—sarcoma	0.000386	0.00268	CcSEcCtD
Fluticasone Propionate—Arthralgia—Mitoxantrone—sarcoma	0.000386	0.00268	CcSEcCtD
Fluticasone Propionate—Anxiety—Mitoxantrone—sarcoma	0.000384	0.00267	CcSEcCtD
Fluticasone Propionate—Discomfort—Mitoxantrone—sarcoma	0.000381	0.00265	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Vincristine—sarcoma	0.00038	0.00264	CcSEcCtD
Fluticasone Propionate—Oedema—Vincristine—sarcoma	0.00038	0.00264	CcSEcCtD
Fluticasone Propionate—Infection—Vincristine—sarcoma	0.000377	0.00262	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.000374	0.0369	CbGpPWpGaD
Fluticasone Propionate—Diabetes mellitus—Doxorubicin—sarcoma	0.000373	0.00259	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Vincristine—sarcoma	0.000372	0.00259	CcSEcCtD
Fluticasone Propionate—NR3C1—testis—sarcoma	0.00037	0.00791	CbGeAlD
Fluticasone Propionate—Anaphylactic shock—Mitoxantrone—sarcoma	0.00037	0.00257	CcSEcCtD
Fluticasone Propionate—Oedema—Mitoxantrone—sarcoma	0.00037	0.00257	CcSEcCtD
Fluticasone Propionate—Infection—Mitoxantrone—sarcoma	0.000367	0.00255	CcSEcCtD
Fluticasone Propionate—Dermatitis bullous—Epirubicin—sarcoma	0.000367	0.00255	CcSEcCtD
Fluticasone Propionate—Pain—Thiotepa—sarcoma	0.000366	0.00254	CcSEcCtD
Fluticasone Propionate—Pain—Dactinomycin—sarcoma	0.000363	0.00252	CcSEcCtD
Fluticasone Propionate—Anaphylactoid reaction—Epirubicin—sarcoma	0.000362	0.00252	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Etoposide—sarcoma	0.000362	0.00252	CcSEcCtD
Fluticasone Propionate—Eczema—Doxorubicin—sarcoma	0.000361	0.00251	CcSEcCtD
Fluticasone Propionate—PGR—Validated nuclear estrogen receptor alpha network—COL18A1—sarcoma	0.000361	0.0356	CbGpPWpGaD
Fluticasone Propionate—Tachycardia—Mitoxantrone—sarcoma	0.000361	0.00251	CcSEcCtD
Fluticasone Propionate—Skin disorder—Mitoxantrone—sarcoma	0.000359	0.0025	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Thiotepa—sarcoma	0.000353	0.00245	CcSEcCtD
Fluticasone Propionate—CYP3A5—liver—sarcoma	0.000352	0.00753	CbGeAlD
Fluticasone Propionate—Feeling abnormal—Dactinomycin—sarcoma	0.00035	0.00243	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Thiotepa—sarcoma	0.00035	0.00243	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Etoposide—sarcoma	0.00035	0.00243	CcSEcCtD
Fluticasone Propionate—NR3C1—liver—sarcoma	0.00035	0.00747	CbGeAlD
Fluticasone Propionate—Gastrointestinal pain—Dactinomycin—sarcoma	0.000348	0.00241	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Vincristine—sarcoma	0.000346	0.0024	CcSEcCtD
Fluticasone Propionate—Urticaria—Thiotepa—sarcoma	0.00034	0.00236	CcSEcCtD
Fluticasone Propionate—Malaise—Etoposide—sarcoma	0.00034	0.00236	CcSEcCtD
Fluticasone Propionate—Dermatitis bullous—Doxorubicin—sarcoma	0.00034	0.00236	CcSEcCtD
Fluticasone Propionate—Face oedema—Epirubicin—sarcoma	0.000339	0.00235	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Thiotepa—sarcoma	0.000338	0.00235	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Thiotepa—sarcoma	0.000338	0.00235	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000337	0.00234	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Dactinomycin—sarcoma	0.000336	0.00233	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Dactinomycin—sarcoma	0.000336	0.00233	CcSEcCtD
Fluticasone Propionate—Anaphylactoid reaction—Doxorubicin—sarcoma	0.000335	0.00233	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Mitoxantrone—sarcoma	0.00033	0.00229	CcSEcCtD
Fluticasone Propionate—Cough—Etoposide—sarcoma	0.000329	0.00228	CcSEcCtD
Fluticasone Propionate—Hypertension—Etoposide—sarcoma	0.000325	0.00226	CcSEcCtD
Fluticasone Propionate—Pain—Vincristine—sarcoma	0.000325	0.00226	CcSEcCtD
Fluticasone Propionate—Chest pain—Etoposide—sarcoma	0.000321	0.00223	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000319	0.00221	CcSEcCtD
Fluticasone Propionate—Discomfort—Etoposide—sarcoma	0.000317	0.0022	CcSEcCtD
Fluticasone Propionate—Pain—Mitoxantrone—sarcoma	0.000316	0.0022	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Thiotepa—sarcoma	0.000315	0.00219	CcSEcCtD
Fluticasone Propionate—Nasopharyngitis—Epirubicin—sarcoma	0.000314	0.00218	CcSEcCtD
Fluticasone Propionate—Face oedema—Doxorubicin—sarcoma	0.000313	0.00218	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Dactinomycin—sarcoma	0.000313	0.00218	CcSEcCtD
Fluticasone Propionate—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—sarcoma	0.000312	0.0308	CbGpPWpGaD
Fluticasone Propionate—Gastrointestinal pain—Vincristine—sarcoma	0.00031	0.00216	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Etoposide—sarcoma	0.000308	0.00214	CcSEcCtD
Fluticasone Propionate—Infection—Etoposide—sarcoma	0.000306	0.00212	CcSEcCtD
Fluticasone Propionate—Abdominal distension—Epirubicin—sarcoma	0.000305	0.00212	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Mitoxantrone—sarcoma	0.000305	0.00212	CcSEcCtD
Fluticasone Propionate—Asthma—Epirubicin—sarcoma	0.000303	0.00211	CcSEcCtD
Fluticasone Propionate—Pruritus—Thiotepa—sarcoma	0.000303	0.0021	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000302	0.0021	CcSEcCtD
Fluticasone Propionate—Tachycardia—Etoposide—sarcoma	0.0003	0.00209	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Vincristine—sarcoma	0.0003	0.00209	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Vincristine—sarcoma	0.0003	0.00209	CcSEcCtD
Fluticasone Propionate—Skin disorder—Etoposide—sarcoma	0.000299	0.00208	CcSEcCtD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—EZR—sarcoma	0.000297	0.0293	CbGpPWpGaD
Fluticasone Propionate—Urticaria—Mitoxantrone—sarcoma	0.000294	0.00204	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Thiotepa—sarcoma	0.000293	0.00204	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Mitoxantrone—sarcoma	0.000292	0.00203	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Mitoxantrone—sarcoma	0.000292	0.00203	CcSEcCtD
Fluticasone Propionate—Bronchitis—Epirubicin—sarcoma	0.000292	0.00203	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Dactinomycin—sarcoma	0.000291	0.00202	CcSEcCtD
Fluticasone Propionate—Nasopharyngitis—Doxorubicin—sarcoma	0.00029	0.00202	CcSEcCtD
Fluticasone Propionate—Dizziness—Thiotepa—sarcoma	0.000283	0.00197	CcSEcCtD
Fluticasone Propionate—Abdominal distension—Doxorubicin—sarcoma	0.000282	0.00196	CcSEcCtD
Fluticasone Propionate—Upper respiratory tract infection—Epirubicin—sarcoma	0.000282	0.00196	CcSEcCtD
Fluticasone Propionate—Asthma—Doxorubicin—sarcoma	0.000281	0.00195	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Vincristine—sarcoma	0.00028	0.00194	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Etoposide—sarcoma	0.000274	0.00191	CcSEcCtD
Fluticasone Propionate—Hyperglycaemia—Epirubicin—sarcoma	0.000273	0.0019	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Mitoxantrone—sarcoma	0.000272	0.00189	CcSEcCtD
Fluticasone Propionate—Vomiting—Thiotepa—sarcoma	0.000272	0.00189	CcSEcCtD
Fluticasone Propionate—Pneumonia—Epirubicin—sarcoma	0.000272	0.00189	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.00027	0.0267	CbGpPWpGaD
Fluticasone Propionate—Infestation NOS—Epirubicin—sarcoma	0.00027	0.00188	CcSEcCtD
Fluticasone Propionate—Infestation—Epirubicin—sarcoma	0.00027	0.00188	CcSEcCtD
Fluticasone Propionate—Vomiting—Dactinomycin—sarcoma	0.00027	0.00188	CcSEcCtD
Fluticasone Propionate—Rash—Thiotepa—sarcoma	0.00027	0.00188	CcSEcCtD
Fluticasone Propionate—Bronchitis—Doxorubicin—sarcoma	0.00027	0.00187	CcSEcCtD
Fluticasone Propionate—Dermatitis—Thiotepa—sarcoma	0.00027	0.00187	CcSEcCtD
Fluticasone Propionate—Headache—Thiotepa—sarcoma	0.000268	0.00186	CcSEcCtD
Fluticasone Propionate—NR3C1—lymph node—sarcoma	0.000268	0.00573	CbGeAlD
Fluticasone Propionate—Rash—Dactinomycin—sarcoma	0.000268	0.00186	CcSEcCtD
Fluticasone Propionate—CYP3A4—liver—sarcoma	0.000264	0.00565	CbGeAlD
Fluticasone Propionate—Pain—Etoposide—sarcoma	0.000263	0.00183	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Epirubicin—sarcoma	0.000263	0.00183	CcSEcCtD
Fluticasone Propionate—PLA2G4A—PDGF Pathway—PLCG1—sarcoma	0.000261	0.0258	CbGpPWpGaD
Fluticasone Propionate—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000261	0.00181	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Vincristine—sarcoma	0.00026	0.0018	CcSEcCtD
Fluticasone Propionate—Epistaxis—Epirubicin—sarcoma	0.000255	0.00177	CcSEcCtD
Fluticasone Propionate—Nausea—Thiotepa—sarcoma	0.000254	0.00177	CcSEcCtD
Fluticasone Propionate—Sinusitis—Epirubicin—sarcoma	0.000254	0.00176	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Etoposide—sarcoma	0.000253	0.00176	CcSEcCtD
Fluticasone Propionate—Hyperglycaemia—Doxorubicin—sarcoma	0.000253	0.00176	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Mitoxantrone—sarcoma	0.000253	0.00176	CcSEcCtD
Fluticasone Propionate—Nausea—Dactinomycin—sarcoma	0.000252	0.00175	CcSEcCtD
Fluticasone Propionate—Pneumonia—Doxorubicin—sarcoma	0.000252	0.00175	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Etoposide—sarcoma	0.000252	0.00175	CcSEcCtD
Fluticasone Propionate—Dizziness—Vincristine—sarcoma	0.000251	0.00174	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Doxorubicin—sarcoma	0.00025	0.00174	CcSEcCtD
Fluticasone Propionate—Infestation—Doxorubicin—sarcoma	0.00025	0.00174	CcSEcCtD
Fluticasone Propionate—Urticaria—Etoposide—sarcoma	0.000244	0.0017	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Etoposide—sarcoma	0.000243	0.00169	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Etoposide—sarcoma	0.000243	0.00169	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Doxorubicin—sarcoma	0.000243	0.00169	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Epirubicin—sarcoma	0.000241	0.00168	CcSEcCtD
Fluticasone Propionate—Vomiting—Vincristine—sarcoma	0.000241	0.00168	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Epirubicin—sarcoma	0.000241	0.00167	CcSEcCtD
Fluticasone Propionate—Rash—Vincristine—sarcoma	0.000239	0.00166	CcSEcCtD
Fluticasone Propionate—Dermatitis—Vincristine—sarcoma	0.000239	0.00166	CcSEcCtD
Fluticasone Propionate—Connective tissue disorder—Epirubicin—sarcoma	0.000238	0.00166	CcSEcCtD
Fluticasone Propionate—Headache—Vincristine—sarcoma	0.000238	0.00165	CcSEcCtD
Fluticasone Propionate—Epistaxis—Doxorubicin—sarcoma	0.000236	0.00164	CcSEcCtD
Fluticasone Propionate—Vomiting—Mitoxantrone—sarcoma	0.000235	0.00163	CcSEcCtD
Fluticasone Propionate—Sinusitis—Doxorubicin—sarcoma	0.000235	0.00163	CcSEcCtD
Fluticasone Propionate—Rash—Mitoxantrone—sarcoma	0.000233	0.00162	CcSEcCtD
Fluticasone Propionate—Dermatitis—Mitoxantrone—sarcoma	0.000233	0.00162	CcSEcCtD
Fluticasone Propionate—Headache—Mitoxantrone—sarcoma	0.000232	0.00161	CcSEcCtD
Fluticasone Propionate—Eye disorder—Epirubicin—sarcoma	0.000227	0.00158	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Etoposide—sarcoma	0.000227	0.00157	CcSEcCtD
Fluticasone Propionate—Nausea—Vincristine—sarcoma	0.000226	0.00157	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Epirubicin—sarcoma	0.000225	0.00156	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Doxorubicin—sarcoma	0.000223	0.00155	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Doxorubicin—sarcoma	0.000223	0.00155	CcSEcCtD
Fluticasone Propionate—Connective tissue disorder—Doxorubicin—sarcoma	0.000221	0.00153	CcSEcCtD
Fluticasone Propionate—Nausea—Mitoxantrone—sarcoma	0.00022	0.00153	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Epirubicin—sarcoma	0.000219	0.00152	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Epirubicin—sarcoma	0.000219	0.00152	CcSEcCtD
Fluticasone Propionate—Pruritus—Etoposide—sarcoma	0.000218	0.00151	CcSEcCtD
Fluticasone Propionate—Arrhythmia—Epirubicin—sarcoma	0.000217	0.00151	CcSEcCtD
Fluticasone Propionate—Mental disorder—Epirubicin—sarcoma	0.000213	0.00148	CcSEcCtD
Fluticasone Propionate—Erythema—Epirubicin—sarcoma	0.000211	0.00147	CcSEcCtD
Fluticasone Propionate—Malnutrition—Epirubicin—sarcoma	0.000211	0.00147	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Etoposide—sarcoma	0.00021	0.00146	CcSEcCtD
Fluticasone Propionate—Eye disorder—Doxorubicin—sarcoma	0.00021	0.00146	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Doxorubicin—sarcoma	0.000208	0.00145	CcSEcCtD
Fluticasone Propionate—NR3C1—Transcription factor regulation in adipogenesis—FOXO1—sarcoma	0.000207	0.0205	CbGpPWpGaD
Fluticasone Propionate—Dizziness—Etoposide—sarcoma	0.000203	0.00141	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Epirubicin—sarcoma	0.000203	0.00141	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Doxorubicin—sarcoma	0.000203	0.00141	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Doxorubicin—sarcoma	0.000202	0.00141	CcSEcCtD
Fluticasone Propionate—Arrhythmia—Doxorubicin—sarcoma	0.000201	0.00139	CcSEcCtD
Fluticasone Propionate—Vision blurred—Epirubicin—sarcoma	0.000199	0.00138	CcSEcCtD
Fluticasone Propionate—Mental disorder—Doxorubicin—sarcoma	0.000197	0.00137	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Epirubicin—sarcoma	0.000196	0.00136	CcSEcCtD
Fluticasone Propionate—Vomiting—Etoposide—sarcoma	0.000196	0.00136	CcSEcCtD
Fluticasone Propionate—Malnutrition—Doxorubicin—sarcoma	0.000195	0.00136	CcSEcCtD
Fluticasone Propionate—Erythema—Doxorubicin—sarcoma	0.000195	0.00136	CcSEcCtD
Fluticasone Propionate—Agitation—Epirubicin—sarcoma	0.000194	0.00135	CcSEcCtD
Fluticasone Propionate—Rash—Etoposide—sarcoma	0.000194	0.00135	CcSEcCtD
Fluticasone Propionate—Dermatitis—Etoposide—sarcoma	0.000194	0.00135	CcSEcCtD
Fluticasone Propionate—Headache—Etoposide—sarcoma	0.000193	0.00134	CcSEcCtD
Fluticasone Propionate—Malaise—Epirubicin—sarcoma	0.000191	0.00132	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Doxorubicin—sarcoma	0.000188	0.00131	CcSEcCtD
Fluticasone Propionate—Palpitations—Epirubicin—sarcoma	0.000187	0.0013	CcSEcCtD
Fluticasone Propionate—PLA2G4A—PDGF Pathway—PDGFRB—sarcoma	0.000185	0.0183	CbGpPWpGaD
Fluticasone Propionate—Cough—Epirubicin—sarcoma	0.000184	0.00128	CcSEcCtD
Fluticasone Propionate—Vision blurred—Doxorubicin—sarcoma	0.000184	0.00128	CcSEcCtD
Fluticasone Propionate—Nausea—Etoposide—sarcoma	0.000183	0.00127	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PLCG1—sarcoma	0.000182	0.018	CbGpPWpGaD
Fluticasone Propionate—Hypertension—Epirubicin—sarcoma	0.000182	0.00127	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Doxorubicin—sarcoma	0.000181	0.00126	CcSEcCtD
Fluticasone Propionate—Chest pain—Epirubicin—sarcoma	0.00018	0.00125	CcSEcCtD
Fluticasone Propionate—Arthralgia—Epirubicin—sarcoma	0.00018	0.00125	CcSEcCtD
Fluticasone Propionate—Agitation—Doxorubicin—sarcoma	0.00018	0.00125	CcSEcCtD
Fluticasone Propionate—Anxiety—Epirubicin—sarcoma	0.000179	0.00125	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000179	0.00124	CcSEcCtD
Fluticasone Propionate—Discomfort—Epirubicin—sarcoma	0.000178	0.00123	CcSEcCtD
Fluticasone Propionate—Malaise—Doxorubicin—sarcoma	0.000176	0.00122	CcSEcCtD
Fluticasone Propionate—Dry mouth—Epirubicin—sarcoma	0.000176	0.00122	CcSEcCtD
Fluticasone Propionate—Palpitations—Doxorubicin—sarcoma	0.000173	0.0012	CcSEcCtD
Fluticasone Propionate—Oedema—Epirubicin—sarcoma	0.000172	0.0012	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Epirubicin—sarcoma	0.000172	0.0012	CcSEcCtD
Fluticasone Propionate—Infection—Epirubicin—sarcoma	0.000171	0.00119	CcSEcCtD
Fluticasone Propionate—Cough—Doxorubicin—sarcoma	0.000171	0.00119	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Epirubicin—sarcoma	0.000169	0.00117	CcSEcCtD
Fluticasone Propionate—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—CREB1—sarcoma	0.000169	0.0167	CbGpPWpGaD
Fluticasone Propionate—Hypertension—Doxorubicin—sarcoma	0.000169	0.00117	CcSEcCtD
Fluticasone Propionate—Tachycardia—Epirubicin—sarcoma	0.000168	0.00117	CcSEcCtD
Fluticasone Propionate—Skin disorder—Epirubicin—sarcoma	0.000167	0.00116	CcSEcCtD
Fluticasone Propionate—Arthralgia—Doxorubicin—sarcoma	0.000166	0.00116	CcSEcCtD
Fluticasone Propionate—Chest pain—Doxorubicin—sarcoma	0.000166	0.00116	CcSEcCtD
Fluticasone Propionate—Anxiety—Doxorubicin—sarcoma	0.000166	0.00115	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Ca-dependent events—CREB1—sarcoma	0.000166	0.0164	CbGpPWpGaD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000165	0.00115	CcSEcCtD
Fluticasone Propionate—Discomfort—Doxorubicin—sarcoma	0.000164	0.00114	CcSEcCtD
Fluticasone Propionate—Dry mouth—Doxorubicin—sarcoma	0.000163	0.00113	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Doxorubicin—sarcoma	0.00016	0.00111	CcSEcCtD
Fluticasone Propionate—Oedema—Doxorubicin—sarcoma	0.00016	0.00111	CcSEcCtD
Fluticasone Propionate—Infection—Doxorubicin—sarcoma	0.000158	0.0011	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000157	0.00109	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Doxorubicin—sarcoma	0.000156	0.00109	CcSEcCtD
Fluticasone Propionate—Tachycardia—Doxorubicin—sarcoma	0.000156	0.00108	CcSEcCtD
Fluticasone Propionate—Skin disorder—Doxorubicin—sarcoma	0.000155	0.00108	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Epirubicin—sarcoma	0.000154	0.00107	CcSEcCtD
Fluticasone Propionate—NR3C1—Transcription factor regulation in adipogenesis—CREB1—sarcoma	0.00015	0.0148	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—p38 MAPK Signaling Pathway—CREB1—sarcoma	0.00015	0.0148	CbGpPWpGaD
Fluticasone Propionate—Pain—Epirubicin—sarcoma	0.000147	0.00102	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.000146	0.0145	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.000145	0.0144	CbGpPWpGaD
Fluticasone Propionate—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000145	0.00101	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Doxorubicin—sarcoma	0.000142	0.000988	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Epirubicin—sarcoma	0.000142	0.000987	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Epirubicin—sarcoma	0.000141	0.00098	CcSEcCtD
Fluticasone Propionate—Urticaria—Epirubicin—sarcoma	0.000137	0.000952	CcSEcCtD
Fluticasone Propionate—Pain—Doxorubicin—sarcoma	0.000136	0.000948	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Epirubicin—sarcoma	0.000136	0.000947	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Epirubicin—sarcoma	0.000136	0.000947	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Doxorubicin—sarcoma	0.000131	0.000913	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Doxorubicin—sarcoma	0.00013	0.000906	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Epirubicin—sarcoma	0.000127	0.000883	CcSEcCtD
Fluticasone Propionate—Urticaria—Doxorubicin—sarcoma	0.000127	0.00088	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Doxorubicin—sarcoma	0.000126	0.000876	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Doxorubicin—sarcoma	0.000126	0.000876	CcSEcCtD
Fluticasone Propionate—PLA2G4A—ADP signalling through P2Y purinoceptor 1—SRC—sarcoma	0.000124	0.0122	CbGpPWpGaD
Fluticasone Propionate—Pruritus—Epirubicin—sarcoma	0.000122	0.000847	CcSEcCtD
Fluticasone Propionate—PLA2G4A—PLC beta mediated events—CREB1—sarcoma	0.000122	0.012	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—FOXO1—sarcoma	0.000122	0.012	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—G-protein mediated events—CREB1—sarcoma	0.00012	0.0118	CbGpPWpGaD
Fluticasone Propionate—Diarrhoea—Epirubicin—sarcoma	0.000118	0.00082	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Doxorubicin—sarcoma	0.000118	0.000817	CcSEcCtD
Fluticasone Propionate—Dizziness—Epirubicin—sarcoma	0.000114	0.000792	CcSEcCtD
Fluticasone Propionate—Pruritus—Doxorubicin—sarcoma	0.000113	0.000784	CcSEcCtD
Fluticasone Propionate—Vomiting—Epirubicin—sarcoma	0.00011	0.000762	CcSEcCtD
Fluticasone Propionate—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000109	0.0108	CbGpPWpGaD
Fluticasone Propionate—Diarrhoea—Doxorubicin—sarcoma	0.000109	0.000758	CcSEcCtD
Fluticasone Propionate—Rash—Epirubicin—sarcoma	0.000109	0.000755	CcSEcCtD
Fluticasone Propionate—Dermatitis—Epirubicin—sarcoma	0.000109	0.000755	CcSEcCtD
Fluticasone Propionate—Headache—Epirubicin—sarcoma	0.000108	0.00075	CcSEcCtD
Fluticasone Propionate—Dizziness—Doxorubicin—sarcoma	0.000105	0.000733	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.000105	0.0104	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signal amplification—SRC—sarcoma	0.000104	0.0103	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—PLCG1—sarcoma	0.000103	0.0101	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.000103	0.0101	CbGpPWpGaD
Fluticasone Propionate—Nausea—Epirubicin—sarcoma	0.000102	0.000712	CcSEcCtD
Fluticasone Propionate—Vomiting—Doxorubicin—sarcoma	0.000101	0.000705	CcSEcCtD
Fluticasone Propionate—Rash—Doxorubicin—sarcoma	0.000101	0.000699	CcSEcCtD
Fluticasone Propionate—Dermatitis—Doxorubicin—sarcoma	0.0001	0.000698	CcSEcCtD
Fluticasone Propionate—Headache—Doxorubicin—sarcoma	9.99e-05	0.000694	CcSEcCtD
Fluticasone Propionate—PLA2G4A—PDGF Pathway—JUN—sarcoma	9.66e-05	0.00954	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	9.62e-05	0.0095	CbGpPWpGaD
Fluticasone Propionate—Nausea—Doxorubicin—sarcoma	9.48e-05	0.000658	CcSEcCtD
Fluticasone Propionate—PLA2G4A—p38 MAPK Signaling Pathway—MYC—sarcoma	8.67e-05	0.00856	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGF Pathway—SRC—sarcoma	8.67e-05	0.00855	CbGpPWpGaD
Fluticasone Propionate—NR3C1—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	8.63e-05	0.00852	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—VEGFC—sarcoma	8.29e-05	0.00819	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—MMP2—sarcoma	8.21e-05	0.0081	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—FUS—sarcoma	8.05e-05	0.00795	CbGpPWpGaD
Fluticasone Propionate—PGR—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	7.97e-05	0.00787	CbGpPWpGaD
Fluticasone Propionate—PGR—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	7.96e-05	0.00786	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—FOXO1—sarcoma	7.64e-05	0.00754	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—PDGFRB—sarcoma	7.62e-05	0.00752	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—PDGFRA—sarcoma	7.5e-05	0.00741	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Opioid Signalling—CREB1—sarcoma	7.49e-05	0.00739	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	7.3e-05	0.00721	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—PDGFRB—sarcoma	7.28e-05	0.00719	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Circadian Clock—CREB1—sarcoma	7.22e-05	0.00713	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	6.95e-05	0.00686	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—sarcoma	6.81e-05	0.00672	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—sarcoma	6.75e-05	0.00667	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Endothelins—JUN—sarcoma	6.58e-05	0.0065	CbGpPWpGaD
Fluticasone Propionate—PGR—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	6.4e-05	0.00631	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—JUN—sarcoma	6.34e-05	0.00626	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of Androgen receptor activity—MDM2—sarcoma	6.15e-05	0.00607	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGF Pathway—HRAS—sarcoma	6.1e-05	0.00602	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—CREB1—sarcoma	5.95e-05	0.00588	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Endothelins—SRC—sarcoma	5.9e-05	0.00583	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—TEK—sarcoma	5.82e-05	0.00575	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—KIT—sarcoma	5.82e-05	0.00574	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—SRC—sarcoma	5.69e-05	0.00562	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—CREB1—sarcoma	5.54e-05	0.00547	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of Androgen receptor activity—JUN—sarcoma	5.35e-05	0.00528	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—ANGPT2—sarcoma	5.33e-05	0.00526	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	5.3e-05	0.00523	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—CREB1—sarcoma	5.24e-05	0.00518	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	5.11e-05	0.00504	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	5.08e-05	0.00502	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—FOXO1—sarcoma	5e-05	0.00494	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—EGFR—sarcoma	4.99e-05	0.00492	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—FUS—sarcoma	4.9e-05	0.00484	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of Androgen receptor activity—SRC—sarcoma	4.8e-05	0.00474	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—MDM2—sarcoma	4.58e-05	0.00452	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—IL2—sarcoma	4.4e-05	0.00434	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Endoderm Differentiation—CTNNB1—sarcoma	4.35e-05	0.00429	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—MDM2—sarcoma	4.34e-05	0.00428	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—CCND1—sarcoma	4.29e-05	0.00424	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—JUN—sarcoma	4.28e-05	0.00423	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—VEGFC—sarcoma	4.27e-05	0.00422	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—sarcoma	4.26e-05	0.00421	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—CTNNB1—sarcoma	4.25e-05	0.00419	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Endothelins—HRAS—sarcoma	4.16e-05	0.0041	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—IL2—sarcoma	3.88e-05	0.00383	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	3.81e-05	0.00376	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—JUN—sarcoma	3.8e-05	0.00376	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—JUN—sarcoma	3.77e-05	0.00372	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	3.77e-05	0.00372	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—CREB1—sarcoma	3.63e-05	0.00358	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—MYC—sarcoma	3.44e-05	0.0034	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—NRAS—sarcoma	3.44e-05	0.00339	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—SRC—sarcoma	3.41e-05	0.00337	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—PLCG1—sarcoma	3.36e-05	0.00332	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—NRAS—sarcoma	3.28e-05	0.00324	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—CREB1—sarcoma	3.14e-05	0.0031	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—EGFR—sarcoma	3.13e-05	0.00309	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	3.12e-05	0.00308	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	3.06e-05	0.00302	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—MYC—sarcoma	3.06e-05	0.00302	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—KRAS—sarcoma	2.96e-05	0.00292	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—FUS—sarcoma	2.84e-05	0.0028	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—TP53—sarcoma	2.83e-05	0.00279	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—KRAS—sarcoma	2.83e-05	0.00279	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.72e-05	0.00268	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.71e-05	0.00268	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.69e-05	0.00266	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—CTNNB1—sarcoma	2.59e-05	0.00256	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—HRAS—sarcoma	2.51e-05	0.00248	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—TP53—sarcoma	2.49e-05	0.00246	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—IL2—sarcoma	2.48e-05	0.00245	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.43e-05	0.0024	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—HRAS—sarcoma	2.4e-05	0.00237	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.37e-05	0.00234	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	2.28e-05	0.00225	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—JUN—sarcoma	2.25e-05	0.00223	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—CTNNB1—sarcoma	2.24e-05	0.00221	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.18e-05	0.00215	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Generic Transcription Pathway—MYC—sarcoma	2.18e-05	0.00215	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—SRC—sarcoma	2.16e-05	0.00214	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.13e-05	0.0021	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—sarcoma	2.11e-05	0.00208	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TLE1—sarcoma	2.1e-05	0.00208	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.01e-05	0.00199	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—VEGFA—sarcoma	1.97e-05	0.00194	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—CXCR4—sarcoma	1.85e-05	0.00183	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.79e-05	0.00177	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—VEGFC—sarcoma	1.77e-05	0.00175	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TLE1—sarcoma	1.72e-05	0.0017	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—ENO2—sarcoma	1.61e-05	0.00158	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—HBA1—sarcoma	1.59e-05	0.00157	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—VEGFC—sarcoma	1.45e-05	0.00143	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—FLT1—sarcoma	1.42e-05	0.0014	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PLCG1—sarcoma	1.39e-05	0.00138	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PLCG1—sarcoma	1.36e-05	0.00134	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CXCR4—sarcoma	1.34e-05	0.00132	CbGpPWpGaD
Fluticasone Propionate—PGR—Generic Transcription Pathway—MYC—sarcoma	1.32e-05	0.00131	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—ATF1—sarcoma	1.32e-05	0.00131	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—IL2—sarcoma	1.28e-05	0.00126	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—FLT1—sarcoma	1.16e-05	0.00114	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PLCG1—sarcoma	1.14e-05	0.00112	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—ENO2—sarcoma	1.12e-05	0.0011	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—SRC—sarcoma	1.12e-05	0.0011	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—HBA1—sarcoma	1.11e-05	0.0011	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CXCR4—sarcoma	1.09e-05	0.00108	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—VEGFA—sarcoma	1.09e-05	0.00107	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—ATF1—sarcoma	1.08e-05	0.00107	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—NRAS—sarcoma	1.07e-05	0.00106	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—MYC—sarcoma	1.05e-05	0.00103	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—IGF1R—sarcoma	1.04e-05	0.00103	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—CREB1—sarcoma	9.92e-06	0.000979	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—FOXO1—sarcoma	9.89e-06	0.000976	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PDGFRB—sarcoma	9.87e-06	0.000975	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PDGFRA—sarcoma	9.72e-06	0.00096	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PLCG1—sarcoma	9.49e-06	0.000937	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—KRAS—sarcoma	9.23e-06	0.000912	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—IGF1R—sarcoma	8.49e-06	0.000838	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—TP53—sarcoma	8.21e-06	0.00081	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—KDR—sarcoma	8.18e-06	0.000808	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—ENO2—sarcoma	8.09e-06	0.000798	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—FOXO1—sarcoma	8.08e-06	0.000798	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PDGFRB—sarcoma	8.07e-06	0.000796	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—HBA1—sarcoma	8.03e-06	0.000793	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PDGFRA—sarcoma	7.94e-06	0.000784	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—HRAS—sarcoma	7.85e-06	0.000775	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—MYC—sarcoma	7.66e-06	0.000756	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—KIT—sarcoma	7.54e-06	0.000744	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—IL2—sarcoma	7.33e-06	0.000724	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CREB1—sarcoma	7.17e-06	0.000708	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PLCG1—sarcoma	6.86e-06	0.000677	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—KDR—sarcoma	6.68e-06	0.00066	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—MYC—sarcoma	6.38e-06	0.00063	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—KIT—sarcoma	6.16e-06	0.000608	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—NRAS—sarcoma	6.16e-06	0.000608	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MDM2—sarcoma	5.94e-06	0.000586	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CREB1—sarcoma	5.86e-06	0.000579	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—EGFR—sarcoma	5.61e-06	0.000554	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—IL2—sarcoma	5.3e-06	0.000524	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—KRAS—sarcoma	5.3e-06	0.000523	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CCND1—sarcoma	5.17e-06	0.00051	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—JUN—sarcoma	5.16e-06	0.000509	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CTNNB1—sarcoma	5.12e-06	0.000505	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MDM2—sarcoma	4.85e-06	0.000479	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—SRC—sarcoma	4.63e-06	0.000457	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—VEGFA—sarcoma	4.51e-06	0.000445	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—HRAS—sarcoma	4.5e-06	0.000445	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—NRAS—sarcoma	4.45e-06	0.00044	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—IL2—sarcoma	4.33e-06	0.000428	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CCND1—sarcoma	4.22e-06	0.000417	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—JUN—sarcoma	4.21e-06	0.000416	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CTNNB1—sarcoma	4.18e-06	0.000413	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MYC—sarcoma	4.15e-06	0.000409	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—EGFR—sarcoma	4.06e-06	0.0004	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—KRAS—sarcoma	3.83e-06	0.000378	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—SRC—sarcoma	3.78e-06	0.000373	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—ENO2—sarcoma	3.76e-06	0.000371	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—HBA1—sarcoma	3.74e-06	0.000369	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—MYC—sarcoma	3.69e-06	0.000364	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—VEGFA—sarcoma	3.68e-06	0.000363	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—NRAS—sarcoma	3.64e-06	0.000359	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TP53—sarcoma	3.41e-06	0.000336	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MYC—sarcoma	3.39e-06	0.000334	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—EGFR—sarcoma	3.31e-06	0.000327	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—HRAS—sarcoma	3.26e-06	0.000322	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PLCG1—sarcoma	3.19e-06	0.000315	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—KRAS—sarcoma	3.13e-06	0.000309	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TP53—sarcoma	2.78e-06	0.000275	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—HRAS—sarcoma	2.66e-06	0.000263	CbGpPWpGaD
